Several new investors joined in the funding, including Borealis Ventures, Fidelity Management & Research Company, GV, Sands Capital Ventures, and Spring Mountain Capital. Existing investors include Polaris Partners and Mithril Capital. Phil Ferneau of Borealis Ventures will join the Ankyra Therapeutics' board of directors.

The funding will allow for new studies and phase I clinical trials, as well as advance additional cytokine programs, the company said.